Medical solution company Boston Scientific Corporation (NYSE:BSX) disclosed on Tuesday the completion of the acquisition of Vertiflex Inc for USD465m in an upfront cash deal.
In addition, Boston will announce additional payments contingent on commercial milestones for the next three years.
Vertiflex Inc is a privately-held company that developed and commercialised the Superion Indirect Decompression System, a minimally-invasive device used to improve physical function and reduce pain in patients with lumbar spinal stenosis (LSS) – the narrowing of the spinal canal, which can cause compression of nearby nerves.
Upon closing, the acquisition of Vertiflex adds the only US FDA-approved, commercially-available, minimally-invasive interspinous spacer to Boston's industry-leading pain management portfolio of spinal cord stimulation and radiofrequency ablation.
UroGen's UGN-103 IND accepted by FDA for bladder cancer treatment
MaaT Pharma reveals positive 18-month data for MaaT013 in GI-aGvHD
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients
Soligenix receives orphan drug designation from FDA for active ingredient in SuVax
Candel Therapeutics granted FDA Orphan Drug Designation for CAN-2409 in pancreatic cancer treatment
Lipogems completes patient enrolment in ARISE I US FDA IDE study
Amylyx Pharmaceuticals' AMX0035 shows promising impact on Wolfram syndrome symptoms
Roche attains CE Mark for first companion diagnostic for HER2-low metastatic breast cancer
Cadrenal Therapeutics' tecarfarin receives US FDA Orphan Drug Designation
BioCity Biopharma's BC2027 Phase one study IND application receives US FDA approval
Seres Therapeutics completes patient enrollment for SER-155 Phase 1B trial